Skip to main content
BioCentury Innovations (formerly SciBX)
Feature Story

Company checkpoints

New players in PD-1 combination therapy

By Stephen Parmley, Senior Writer

The spate of biotechs announcing new targets, combinations or milestones in the PD-1 space in the last two months suggests pharmas may not have to wait long to add second-generation therapies to their pipelines of checkpoint inhibitors. While AnaptysBio Inc. and cCAM have preclinical targets that could complement PD-1 inhibition, OncoSec Medical Inc. is about to enter the clinic with a combination that uses PD-1 suppression to potentiate the immune activation of IL-12.

The push for new compounds is driven by the fact that many patients don't respond to PD-1 therapies because their tumors have either low or no expression of the receptor's ligand, PD-L1. By acting through complementary pathways, upregulating the expression of PD-L1 or increasing the ability of antigen-presenting cells to trigger immune pathways, the next generation of compounds is designed to potentiate the tumor-killing effect of PD-1 inhibitors (See Cover Story).

Read Article | PDF

Today's Biotech & Pharma News

  • THE DISTILLERY brings you this week's most essential scientific findings in therapeutics, distilled by Innovations editors from a weekly review of more than 400 papers in 41 of the highest-impact journals in the fields of biotechnology, the life sciences and chemistry. The Distillery goes beyond the abstracts to explain the commercial relevance of featured research, including licensing status and companies working in the field, where applicable.

    This week in therapeutics includes important research findings on targets and compounds, grouped first by disease class and then alphabetically by indication.

    This week in techniques includes findings about research tools, disease models and manufacturing processes that have the potential to enable or improve all stages of drug discovery and development.

Subscribe Now
Free Trial